A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel
Phase 1
Terminated
- Conditions
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2012-05-10
- Lead Sponsor
- Agennix
- Target Recruit Count
- 25
- Registration Number
- NCT00313456
- Locations
- ๐บ๐ธ
Sarah Cannon Research Institute, Nashville, Tennessee, United States
Satraplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-12-23
- Last Posted Date
- 2012-04-30
- Lead Sponsor
- Agennix
- Target Recruit Count
- 40
- Registration Number
- NCT00268970
- Locations
- ๐บ๐ธ
Sarah Cannon Research Institute, Nashville, Tennessee, United States
Satraplatin for Patients With Metastatic Breast Cancer (MBC)
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-12-15
- Last Posted Date
- 2012-03-28
- Lead Sponsor
- Agennix
- Target Recruit Count
- 40
- Registration Number
- NCT00265655
- Locations
- ๐บ๐ธ
US Oncology, Dallas, Texas, United States
Study of Satraplatin (JM-216) in Combination With Docetaxel
Phase 1
Terminated
- Conditions
- First Posted Date
- 2005-08-01
- Last Posted Date
- 2012-03-26
- Lead Sponsor
- Agennix
- Target Recruit Count
- 28
- Registration Number
- NCT00125411
- Locations
- ๐บ๐ธ
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States
Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma
Phase 2
Completed
- Conditions
- First Posted Date
- 2004-11-02
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Agennix
- Target Recruit Count
- 40
- Registration Number
- NCT00095186
- Locations
- ๐บ๐ธ
University of California, Los Angeles, California, United States
๐บ๐ธVA Medical Center/Baylor College of Medicine, Houston, Texas, United States
๐บ๐ธThe University of Chicago Medical Center, Chicago, Illinois, United States
Satraplatin for Locally Advanced Non-Small Cell Lung Cancer With Simultaneous Radiotherapy
- First Posted Date
- 2004-10-04
- Last Posted Date
- 2012-08-17
- Lead Sponsor
- Agennix
- Target Recruit Count
- 20
- Registration Number
- NCT00093132
- Locations
- ๐บ๐ธ
Southwestern Medical Center, Dallas, Texas, United States
Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen
Phase 3
Completed
- Conditions
- First Posted Date
- 2003-10-06
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- Agennix
- Registration Number
- NCT00069745
- Locations
- ๐บ๐ธ
University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States
๐บ๐ธTexas Cancer Center at Medical City, Dallas, Texas, United States
๐ฉ๐ชMarienhospital II, Herne, Germany
ยฉ Copyright 2024. All Rights Reserved by MedPath